Mild cognitive impairment (MCI) is present in up to 34% of patients with early-stage Parkinson disease (PD); however, it is difficult to detect subtle impairment without objective cognitive testing.
Methods:
Data were obtained from the Parkinson Progression Marker Initiative. All 341 participants were administered the Montreal Cognitive Assessment (MoCA) and a brief neuropsychological battery. Participants were classified as PD-MCI if MoCA was <26 or if they scored ≥1 standard deviation below the normative mean in 2 or more domains, based upon established criteria. The sensitivity/specificity for the clinical detection of PD-MCI was determined.
Results:
Overall accuracy for clinical detection of PD-MCI was 67.4%. Although clinical determination was highly specific (96.3%; 95% confidence interval [CI]: 0.92-0.98), sensitivity was poor (32.0%; 95% CI: 0.25-0.40).
Conclusion:
Identifying MCI in early-stage PD based on clinical interview alone appears to be insufficient. The inclusion of objective cognitive tests allowing for normative sample comparisons is needed to increase the detection of cognitive impairment in this population.
StefanovaEZiropadjaLStojkovicT. Mild cognitive impairment in early Parkinson’s disease using the Movement Disorder Society Task Force criteria: cross-sectional study in Hoehn and Yahr Stage 1. Dement Geriatr Cogn Disord. 2015;40(3-4):199–209.
3.
SantangeloGVitaleCPicillioM. Mild cognitive impairment in newly diagnosed Parkinson’s disease: a longitudinal prospective study. Parkinsonism Relat Disord. 2015;21(10):1219–1226.
4.
HobsonPMearaJ. Mild cognitive impairment in Parkinson’s disease and its progression onto dementia: a 16-year outcome evaluation of the Denbighshire cohort. Int J Geriatr Psychiatry. 2015;30(10):1048–1055.
5.
DomellofMEElghEForsgrenL. The relation between cognition and motor dysfunction in drug-naïve newly diagnosed patients with Parkinson’s disease. Mov Disord. 2011;26(12):2183–2189.
6.
StewartR. Mild cognitive impairment: the continuing challenge of its “Real-world” detection and diagnosis. Arch Med Res. 2012;43(8):609–614.
7.
KaduszkiewiczHZimmermannTVan den BusscheH. Do general practitioners recognize mild cognitive impairment in their patients?J Nutr Health Aging. 2010;14(8):697–702.
8.
GoldmanJGLitvanI. Mild cognitive impairment in Parkinson’s disease. Minerva Med. 2011;102(6):441–459.
9.
KehagiaAABarkerRARobbinsTW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol. 2010;9(12):1200–1213.
10.
McKinlayAGraceRCDalrymple-AlfordJCRogerD. Cognitive characteristics associated with mild cognitive impairment in Parkinson’s disease. Dement Geriatr Cogn Disord. 2009;28(2):121–129.
11.
BronnickK. Cognitive profile in Parkinson’s disease dementia. In: EmreM, ed. Cognitive Impairment and Dementia in Parkinson’s Disease. New York, NY: Oxford University Press; 2005:27–43.
12.
AndersonKE. Dementia in Parkinson’s disease. Curr Treat Options Neurol. 2004;6(3):201–207.
13.
MahieuxFFenelonGFlahaultAManifacierMMicheletDBollerF. Neuropsychological prediction of dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1998;64(2):178–183.
14.
MeehlP. Clinical Versus Statistical Prediction: A Theoretical Analysis and a Review of the Evidence. Guilford, VT: Echo Point Books & Media; 2013.
15.
GroveWM. Clinical versus statistical prediction: the contribution of Paul E Meehl. J Clin Psychol. 2005;61(10):1233–1243.
16.
TverskyAKahnemanD. Judgment under uncertainty: heuristics and biases. Science. 1974;185(4157):1124–1131.
17.
GarbHN. Studying the Clinician: Judgment Research and Psychological Assessment. Washington, DC: American Psychological Association; 1998.
18.
ArkesHRWortmannRLSavillePDHarknessAR. Hindsight bias among physicians weigh in the likelihood of diagnoses. J Appl Psychol. 1981;66(2):252–254.
19.
GroveWMZaldDHLebowBSSnitzBENelsonC. Clinical versus mechanical prediction: a meta-analysis. Psychol Assess. 2000;12(1):19–30.
20.
LitvanIGoldmanJGTrosterAI. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement disorder society task force guidelines. Mov Disord. 2012;27(3):349–356.
21.
MarekKJenningsDLaschS. The Parkinson progression marker initiative (PPMI). Prog Neurobiol. 2011;95(4):629–635.
22.
NasreddineZSPhillipsNABedirianV. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699.
23.
BrandtJ. The Hopkins verbal learning test: development of new memory test with six equivalent forms. Clin Neuropsychol. 1991;5(2):125–142.
24.
StrausEShermanEMSpreenO. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. 3rd ed. New York, NY: Oxford University Press; 2006.
25.
SmithA. Symbol Digit Modalities Test. Los Angeles, CA: Western Psychological Services; 1982.
26.
WechslerD. WMS-III Administration and Scoring Manual. The Psychological Corporation; 1997.
MitchellAJMeaderNPentzekM. Clinical recognition of dementia and cognitive impairment in primary care: a meta-analysis of physician accuracy. Acta Psychiatr Scand. 2011;124(3):165–183.
29.
DomellofMEEkmanUForsgrenLElghE. Cognitive function in the early phase of Parkinson’s disease: a five-year follow-up. Acta Neurol Scand. 2015;132(2):79–88.
30.
DuncanGWKhooTKYarnallAJ. Health-related quality of life in early Parkinson’s disease: the impact of nonmotor symptoms. Mov Disord. 2014;29(2):195–202.
31.
ReginoldWDuff-CanningSMeaneyC. Impact of mild cognitive impairment on health-related quality of life in Parkinson’s disease. Dement Geriatr Cogn Disord. 2013;36(1-2):67–75.
32.
MarrasCArmstrongMJMeaneyCA. Measuring mild cognitive impairment in patients with Parkinson’s disease. Mov Disord. 2013;28(5):626–633.
33.
BartonBRBernardBCzerneckiV. Comparison of the movement disorder society Parkinson’s disease dementia criteria with neuropsychological testing. Mov Disord. 2014;29(10):1252–1257.
